Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10239017 | 1.00 | BTK (0.42) | BTKKMT2AL3MBTL1KDM1AMAOB | |
| SCHEMBL25741446 | 0.80 | BTK (0.58) | BTKKMT2AL3MBTL1KDM1AMAOB | |
| SCHEMBL10188583 | 0.77 | PARP10 (0.44) | FFAR4LOXL2NPC1RAB9A | |
| SCHEMBL21389843 | 0.76 | BTK (0.53) | BTKKMT2AGAAMEN1RAB9A | |
| SCHEMBL10188580 | 0.75 | FFAR4 (0.52) | FFAR4 | |
| SCHEMBL15026735 | 0.74 | BTK (0.49) | BTKKMT2AL3MBTL1GAAMEN1 | |
| SCHEMBL25518309 | 0.74 | BTK (0.60) | BTKKMT2AL3MBTL1KDM1AMAOB | |
| SCHEMBL21588244 | 0.73 | GAA (0.55) | BTKKMT2AGAAMEN1RAB9A | |
| SCHEMBL25136336 | 0.72 | KDM1A (0.56) | BTKKMT2AL3MBTL1KDM1AMAOB | |
| SCHEMBL30182719 | 0.72 | KDM1A (0.56) | BTKKMT2AL3MBTL1KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | OXA1L, CYP11B2, CYP11B1 | BTK 366/4885KMT2A 4146/4885L3MBTL1 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.